

Request for Prior Authorization Direct oral anticoagulants

Contains confidential patient information

Complete form in its entirety and fax to: Prior Authorization of Benefits Center at **844-512-9004**.

Provider Help Desk: **800-454-3730**

1. Patient information

Patient name: _____

Patient ID #: _____

Patient DOB: _____

Date of Rx: _____

Patient phone #: _____

Patient email address: _____

2. Physician information

Prescribing physician: _____

Physician address: _____

Physician phone #: _____

Physician fax #: _____

Physician specialty: _____

Physician DEA: _____

Physician NPI #: _____

Physician email address: _____

3. Medication

4. Strength

5. Directions

6. Quantity per 30 days

Specify: _____

7. Diagnosis: _____ _____

8. Approval criteria: (Check all boxes that apply. Note: Any areas not filled out are considered not applicable to your patient and may affect the outcome of this request.)

Prior authorization (PA) is not required for preferred direct oral anticoagulants (DOACs). Prior authorization is required for non-preferred DOACs. Requests will be considered for FDA approved dosing and length of therapy for submitted diagnosis. Requests for doses outside of the manufacturer recommended dose will not be considered. Payment will be considered for FDA approved or compendia indications for the requested drug under the following conditions: 1) Patient is within the FDA labeled age for indication; and 2) Patient does not have a mechanical heart valve; and 3) Patient does not have active bleeding; and 4) For a diagnosis of atrial fibrillation or stroke prevention, patient has the presence of at least one additional risk factor for stroke, with a CHA2DS2-VASc score ≥ 1 ; and 5) A recent creatinine clearance (CrCl) is provided; and 6) A recent Child-Pugh score is provided; and 7) Patient's current body weight is provided; and 8) Patient has documentation of a trial and therapy failure at a therapeutic dose with at least two preferred DOACs; and 9) For requests for edoxaban, when prescribed for the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), documentation patient has had 5 to 10 days of initial therapy with a parenteral anticoagulant (low molecular weight heparin or unfractionated

heparin) is provided. The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.

Preferred (no PA required if within established quantity limits)

- Eliquis
- Xarelto
- Pradaxa

Non-Preferred (PA required)

- Bevyxxa
- Xarelto Suspension
- Savaysa
- Dabigatran

Does patient have mechanical heart valve? Yes No

Does patient have active bleeding? Yes No

Patient body weight: _____ Date obtained: _____

Provide recent creatinine clearance (CrCl): _____ Date obtained: _____

Provide recent Child-Pugh score: _____ Date completed: _____

Requests for a diagnosis of atrial fibrillation or stroke prevention:

Risk factor based CHA ₂ DS ₂ -VASc Score	
Risk Factors	Score
<input type="checkbox"/> Congestive heart failure	1
<input type="checkbox"/> Hypertension	1
<input type="checkbox"/> Age ≥ 75 years	2
<input type="checkbox"/> Age between 65 and 74 years	1
<input type="checkbox"/> Stroke / TIA / TE	2
<input type="checkbox"/> Vascular disease (previous MI, peripheral arterial disease or aortic plaque)	1
<input type="checkbox"/> Diabetes mellitus	1
<input type="checkbox"/> Female	1
Total	

Document 2 preferred DOAC trials:

Preferred DOAC Trial 1: Name/Dose: _____ Trial Dates: _____

Failure reason: _____

Preferred DOAC Trial 2: Name/Dose: _____ Trial Dates: _____

Failure reason: _____

Requests for edoxaban (Savaysa):

Provide documentation of 5 to 10 days of initial therapy with a parenteral anticoagulant (low molecular weight heparin or unfractionated heparin) for diagnosis of DVT or PE:

